1 active not recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
Follow Mark Tuszynski: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment AAV2-BDNF Gene Therapy - Alzheimer's Disease, Mild Cognitive Impairment | Phase 1 | Active not recruiting | Mark Tuszynski | 12 | 2022-02-07 | 2026-07-10 |
Alzheimer Disease (1) · Cognitive Dysfunction (1)
United States (1)
PMID 19198615, PMID 21358740, PMID 24068826, PMID 26302439, PMID 39422960